Metformin in Alzheimer’s dementia Prevention (MAP) Study
*This study is now fully enrolled and no additional subjects are currently being recruited.
Purpose of this Study
MAP is a research study looking at an existing drug used for diabetes prevention. The study tests if this drug can help prevent a decline in memory and thinking abilities for people with mild memory problems. It is a randomized study in which you will take either metformin (Glucophage® XR) or a placebo.
MAP is a multi-center study, where people can take part in the study at 11 locations throughout the United States. It is funded by the National Institutes of Health (NIH) through the National Institute on Aging (NIA). Our researchers are experienced in running research studies. They are also experts in the field of memory loss, dementia, and Alzheimer’s disease. We invite you to join us in our search for treatments to improve the lives of those with memory problems due to Alzheimer’s disease.
You may qualify if:
- You are 55-90 years old
- You or your loved ones have noticed some changes in your memory, and
- You are not already being treated for diabetes or dementia
You may NOT qualify if:
- Live in a nursing home or assisted living facility
- Have diabetes
- Have dementia
- Have a chronic or disabling disease
- You are using metformin or known intolerance to metformin
Duration of the Study:
This is a two-year study with approximately five (5) study visits to the local study site.
Study Procedures:
- Medical history
- Physical examination/assessment
- Blood tests
- Memory and thinking activities
- Monthly check-in calls between visits
- MRI of your brain (optional)
Study Locations:
UT Health San Antonio
Sam and Ann Barshop Institute for Longevity and Aging Studies
4939 Charles Katz Dr.
San Antonio, TX 78229
Compensation:
You may earn up to $1,450 for completing all study-related visits.
Principal Investigator:
Sara Espinoza, MD, MSc
